This Undiscovered Company has 6 Drugs on Market and 5 under review by Health Canada . The Game Changer for Pediapharm is Easyhaler which expected to approved before year end .Another reason to own the Stock is the upcoming US-Partnership for Naproxen which also expected before year end . This Stock is a Lifetime Opportunity .
Pediapharm has submitted its reconsideration package to Health Canada regarding Easyhaler Budesonide. The Company’s objective remains to obtain a marketing approval by the end of 2015.
Furthermore, before the end of 2015, the Company intends to sign an agreement with a US commercial partner for the selling and marketing of its first product acquisition in the US; namely the Pediapharm Naproxen Suspension. Pediapharm believes that with this agreement, the Company will reach profitability more rapidly.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.